Fingolimod | MedChemExpress

MCE 的所有产品仅用作科学研究，我们不为任何个人用途提供产品和服务。

CAS No. : 162359-55-9

MCE 国际站：Fingolimod

产品活性：Fingolimod 是一种 1-磷酸鞘氨醇 (sphingosine 1-phosphate，S1P) 拮抗剂，作用于 K562 和 NK 细胞，IC₅₀ 为 0.033 nM。Fingolimod 还是一种 pak1 激活剂，免疫抑制剂。

研究领域：GPCR/G Protein  |  Cytoskeleton  |  Cell Cycle/DNA Damage

作用靶点：LPL Receptor  |  PAK

In Vitro: The monocyte-derived immature dendritic cells (iDCs) are pretreated with various concentrations of S1P for various periods of time prior to their incubation with NK cells. Four hours incubation of autologous or allogeneic iDCs with 0.2-20 μM of S1P significantly protectes these cells from NK cell lysis. The IC₅₀ values of S1P are calculated at 160 nM for autologous iDCs, and 34 nM for allogeneic iDCs. Next, the inhibitory effect of S1P is revered by various concentrations of Fingolimod or SEW2871, with an IC₅₀ effect of 173 or 15 nM, respectively. Fingolimod has been reported to reduce LPA synthesis via inhibition of the lysophospholipase autotaxin. Fingolimod treatment correlates with a significant elevation of axonal cAMP, a crucial factor for axonal outgrowth. Additionally, Fingolimod significantly reduces LPA levels in the injured nerve. PF-8380 treatment correlates with improved myelin thickness.

In Vivo: Fingolimod treatment results in significantly increased nerve conduction at 14 days post-crush in wildtype C57BL/6 mice. However, Foxn1^-/- mice, which are devoid of T- but not B-lymphocytes, show an improvement of nerve regeneration under fingolimod treatment. Although the mean increase in nerve conduction velocity in both fingolimod-treated and controlFoxn1^-/- mice implies a potentially positive role of T-lymphocyte deficiency on nerve regeneration, only fingolimod-treated Foxn1^-/- mice show a significant improvement compared to C57BL/6 controls and performed better in the functional analysis. Treatment of the animals with Fingolimod for 28 d results in a clear reduction in the binding of ¹⁸F-GE180 when compare with vehicle-treated animals and evaluated by ex vivo autoradiography. Quantification of the binding of the radiotracer revealed a significant reduction in the binding potential of ¹⁸F-GE180 (P<0.0001) after treatment with Fingolimod.

相关产品：FDA-Approved Drug Library Plus  |  Drug Repurposing Compound Library  |  FDA-Approved Drug Library Mini  |  Anti-Aging Compound Library  |  Kinase Inhibitor Library  |  GPCR/G Protein Compound Library  |  CNS-Penetrant Compound Library  |  Anti-COVID-19 Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Cell Cycle/DNA Damage Compound Library  |  Drug Repurposing Compound Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Fingolimod hydrochloride  |  PF-3758309  |  Ki16425  |  FRAX486  |  BMS-986020  |  Ozanimod  |  PF-543 Citrate  |  5-Aminosalicylic Acid  |  IPA-3  |  PF429242 dihydrochloride  |  TY-52156  |  G-5555  |  AM966  |  Etrasimod  |  AM095  |  FRAX1036  |  FRAX597  |  NVS-PAK1-1  |  Amiselimod hydrochloride  |  Cenerimod  |  LPA2 antagonist 1  |  FTY720 (S)-Phosphate  |  KPT-9274  |  ONO-7300243  |  S1p receptor agonist 1  |  Ponesimod  |  GNE 2861  |  CYM-5541

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。